N-Acetyl Selank vs N-Acetyl Semax: Research Profiles Compared
·5 min read
Selank and Semax are the two most studied synthetic nootropic peptides from the Russian research tradition — both heptapeptides, both developed at Moscow research institutions, both registered as medicines in Russia, and both now available in enhanced terminal-modified forms (N-acetyl, amidate) that substantially extend biological half-life. Despite appearing in the same research context repeatedly, they are mechanistically distinct: Selank is primarily a GABAergic anxiolytic with immune-modulatory properties; Semax is primarily a BDNF-upregulating cognitive enhancer. Understanding the difference matters for research protocol design.
01 — Origins and Structure
Selank (TBIO6) is a synthetic analogue of Tuftsin, an endogenous immunopeptide (Thr-Lys-Pro-Arg) produced by the spleen. The base sequence was extended to a heptapeptide — Thr-Lys-Pro-Arg-Pro-Gly-Pro — with modifications that substantially change its pharmacological profile relative to the parent molecule. Developed at the Institute of Molecular Genetics, Russian Academy of Sciences, Selank entered Russian clinical registration as an anxiolytic agent following trials conducted under the Russian Ministry of Health.
Semax is derived from ACTH(4-7), a fragment of adrenocorticotropic hormone, extended with a Pro-Gly-Pro C-terminal sequence to improve stability. The base sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed at the same Institute of Molecular Genetics and received Russian Ministry of Health registration for use in stroke and traumatic brain injury research contexts.
Both compounds gain significantly improved biological half-life through the same terminal modifications:
N-acetylation at the N-terminus blocks aminopeptidase access
Amidation at the C-terminus blocks carboxypeptidase access
These modifications are the primary reason the amidate forms exist — unmodified Selank has a biological half-life of approximately 1–2 minutes in plasma; the modified form is substantially extended. The same logic applies to Semax amidate.
02 — Mechanisms: Where They Diverge
Selank: GABAergic Modulation and Immune Interaction
The primary mechanism associated with Selank's anxiolytic effects in published research is modulation of the GABAergic system. Selank enhances GABA-A receptor activity, increasing inhibitory neurotransmission in a manner mechanistically parallel to benzodiazepines — but through a distinct binding site and without the receptor downregulation and tolerance development documented with classical benzodiazepine use in animal models.
Selank also interacts with the enkephalin system — inhibiting enkephalin-degrading enzymes, extending natural enkephalin activity in stress-response and mood-regulation pathways. And as a Tuftsin analogue, it retains immunomodulatory properties: published studies document modulation of IL-6 and related cytokines, connecting Selank to the immune-cognitive interface.
The research profile: anxiolytic, anti-stress, mild cognitive enhancement secondary to anxiety reduction, immune modulation.
Semax: BDNF Upregulation and Dopaminergic Signalling
Semax acts through a different primary pathway. The dominant effect documented in published research is upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in relevant brain regions — the hippocampus, prefrontal cortex, and related structures involved in memory consolidation and executive function. BDNF is the central mediator of neuroplasticity, and Semax's consistent upregulation of this pathway across published animal studies is the mechanistic basis for its cognitive-enhancing research profile.
Semax also increases dopaminergic and serotonergic tone in the prefrontal cortex in published animal models — effects that parallel the profile of compounds studied in attention and executive function research contexts.
The research profile: cognitive enhancement (memory, learning, attention), neuroprotection, BDNF pathway activation, with anxiolytic effects documented secondarily.
Both compounds are commonly examined via the intranasal route in research protocols. The olfactory epithelium provides direct CNS access bypassing systemic distribution, which is particularly relevant for CNS-active peptides where systemic metabolism would otherwise reduce central bioavailability.
The N-acetyl and amidate modifications are especially important for intranasal administration: mucosal surfaces are rich in peptidases that rapidly degrade unmodified peptides. The terminal modifications allow significantly more compound to reach CNS tissue intact.
Both can also be examined via subcutaneous administration in animal models.
05 — Which for What Research Context
Selank/N-Acetyl Selank Amidate is the appropriate compound for research examining: GABAergic anxiolytic mechanisms without benzodiazepine pharmacology; stress-immune pathway interaction; the relationship between anxiety and cognitive performance; enkephalin system modulation.
Semax/N-Acetyl Semax Amidate is the appropriate compound for research examining: BDNF-mediated neuroplasticity; cognitive enhancement mechanisms; neuroprotective pathways in acute neurological injury models; dopaminergic modulation in prefrontal research contexts.
The two compounds are not redundant — they target different receptor systems and different aspects of the cognitive and stress-response literature. Research protocols examining the full picture of stress-cognition interaction might employ both.
